Does Slower Aquablation Growth at PROCEPT (PRCT) Hint At A Transition In Its Long-Term Story?

• In early December 2025, BofA Securities downgraded PROCEPT BioRobotics from Buy to Neutral, citing slower utilization growth and decelerating system sales for its Aquablation technology amid tighter hospital capital budgets.
• The report still emphasized PROCEPT’s sizable market opportunity and financial flexibility, highlighting a tension between near-term growth concerns and longer-term adoption potential for Aquablation in benign prostatic hyperplasia.
• We’ll now examine how this slowdown in Aquablation utilization growth could influence PROCEPT BioRobotics’ longer-term investment narrative and expectations.

These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

PROCEPT BioRobotics Investment Narrative Recap

To own PROCEPT BioRobotics, you need to believe Aquablation becomes a standard treatment for benign prostatic hyperplasia, supporting sustained procedure and consumable growth even as the company remains loss making. BofA’s downgrade highlights that slower utilization growth could blunt the near term catalyst of rising procedure volumes, while reinforcing the key risk that hospitals may take longer to fully adopt Aquablation systems. For now, the headline does not appear to alter the core long term narrative.

The most relevant recent announcement is PROCEPT’s Q3 2025 update, where management reaffirmed 2025 revenue guidance of about US$325.5 million and introduced 2026 guidance of US$410 million to US$430 million. That guidance sits alongside concerns about decelerating utilization and keeps the spotlight on whether system placements and procedure growth can track expectations, given ongoing operating losses and higher scrutiny on hospital capital spending.

Yet investors should be aware that slower Aquablation utilization growth could compound the risk that...

Read the full narrative on PROCEPT BioRobotics (it's free!)

PROCEPT BioRobotics' narrative projects $563.8 million revenue and $70.4 million earnings by 2028. This requires 27.0% yearly revenue growth and a $154.5 million earnings increase from $-84.1 million today.

Uncover how PROCEPT BioRobotics' forecasts yield a $52.10 fair value, a 53% upside to its current price.

Exploring Other Perspectives

Seven fair value estimates from the Simply Wall St Community span about US$27.50 to US$85 per share, underscoring how differently investors view PROCEPT’s potential. You can weigh those views against the risk that slower Aquablation adoption and tighter hospital budgets may constrain system placements and delay the company’s path toward scaling its recurring revenue base.

Explore 7 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth over 2x more than the current price!

Build Your Own PROCEPT BioRobotics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free PROCEPT BioRobotics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PROCEPT BioRobotics' overall financial health at a glance.

No Opportunity In PROCEPT BioRobotics?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com